Background: Ligands consisting of two aryl moieties connected via a short spacer were shown to be potent inhibitors of monoamine oxidases (MAO) A and B, which are known as suitable targets in treatment of neurological diseases. Based on this general blueprint, we synthesized a series of 66 small aromatic amide derivatives as novel MAO A/B inhibitors. Methods: The compounds were synthesized, purified and structurally confirmed by spectroscopic methods. Fluorimetric enzymological assays were performed to determine MAO A/B inhibition properties. Mode and reversibility of inhibition was determined for the most potent MAO B inhibitor. Docking poses and pharmacophore models were generated to confirm the in vitro results. ST-2043) was found to be a reversible competitive moderately selective MAO B inhibitor (IC 50 = 56 nM, K i = 6.3 nM), while N-(2,4-dinitrophenyl)benzamide (7, ST-2023) showed higher preference for MAO A (IC 50 = 126 nM). Computational analysis confirmed in vitro binding properties, where the anilides examined possessed high surface complementarity to MAO A/B active sites. Conclusion: The small molecule anilides with different substitution patterns were identified as potent MAO A/B inhibitors, which were active in nanomolar concentrations ranges. These small and easily accessible molecules are promising motifs, especially for newly designed multitargeted ligands taking advantage of these fragments. Keywords: salicylic acid derivatives, molecular modeling, Parkinson's disease, enzyme inhibitor, pharmacophore, structure-activity relationships
Plain Language Summary
Monoamine oxidases (MAO) A and B are neurotransmitter-catabolizing enzymes, which play a role in the pathophysiology of neurological diseases such as Parkinson's disease, depression or schizophrenia. Small molecules consisting of two aryl moieties connected via a short spacer were shown to be potent MAO A/B inhibitors. In this study, aromatic amide derivatives with different structural variations and substitution pattern were demonstrated to have MAO A/B inhibition properties in a nanomolar concentration range. Compound 55 was found to be a reversible competitive MAO B preferring inhibitor (IC 50 = 56 nM, K i = 6.3 nM), while compound 7 showed a higher preference for MAO A (IC 50 = 126 nM). Computational analysis confirmed in vitro binding properties as the respective anilides possessed high surface complementarity to MAO A/B active sites. These results suggest that the herein described anilides are small and easily accessible molecules, which may serve as promising precursors for the design of selective or multitargeting MAO A/B inhibitors.
Introduction
The neurotransmitter-catabolizing monoamine oxidases (MAO) are localized in the outer mitochondrial membrane and are classified into the A and B isoforms. MAO A is mainly involved in the degradation of serotonin, melatonin, norepinephrine, and epinephrine, and is expressed nearly ubiquitously in the human body. MAO B breaks down phenethylamine and benzylamine and it is highly expressed in the central nervous system (CNS). Dopamine, tyramine and tryptamine can be metabolized by both isoforms but with individual metabolic activity for each substrate. Consequently, inhibitors of both enzymes are established in the pharmacotherapy for neurological diseases. [1] [2] [3] Moclobemide was the first marketed MAO inhibitor and entered the Swedish market in 1989. 4 Slowing down the degradation of neurotransmitters like dopamine and norepinephrine via MAO A inhibition, this drug exhibits moodlifting properties facilitating its use as an antidepressant. 4 Since then the irreversible nonselective MAO inhibitor tranylcypromine as well as the irreversible MAO B inhibitors rasagiline and selegiline were approved for the treatment of depression and Parkinson's disease (PD), respectively. Recently, safinamide as first reversible MAO B inhibitor in PD therapy was approved. [5] [6] [7] As the imminent therapeutic benefits of MAO inhibitors are nowadays clear, multiple efforts have been made to develop new reversible and irreversible inhibitors. Due to long-term enzyme inactivation by irreversible MAO inhibitors, these can be associated with serious side effects or drug-drug interactions, eg leading to a serotonin syndrome. 8 Reversible MAO inhibitors have a more favorable side effect profile; however, they can be displaced from the active site in case of high levels of the endogenous ligands. To maintain pharmacological efficacy, they are aimed to show a high affinity towards the MAOs and/or tight binding behavior. 9 The design of such reversible and selective inhibitors of MAO A and B became a strongly researched area to identify suitable drug candidates for the treatment of neurological diseases, particularly of PD. Having in mind that such diseases usually derive from multifactorial disorders, the development of sophisticated multitargeted ligands (MTLs) became of major exploration to treat these CNS disorders. 10, 11 The combination of different biological active moieties in one molecule is challenging since the affinity for each target needs to be preserved together with maintaining drug-likeness properties. Identification of small chemical entities with a promising target affinity are of great value in MTL drug design, as they might be easily combined or fused with other pharmacophores with minor influences on molecular size. Accordingly, we synthesized a series of 66 anilides with diverse substitution patterns. The presented anilides are small-sized and have low molecular weights. The ligands show structural similarities to previously described potent MAO inhibitors assuring potential MAO inhibition activities. Multiple publications identified two aromatic moieties linked by a short bridging element as mutual MAO scaffold. 8, [12] [13] [14] [15] [16] Due to their high stability under physiological conditions, amides were used as linkers in our series. Aromatic moieties bearing different substituents were chosen to elucidate electronic and steric effects on the binding affinities towards both MAO isoforms. The presented ligands were characterized in vitro. For a better understanding of the binding modes, computational docking experiments were performed and a ligand-based pharmacophore-model was established.
Materials and Methods

Reagents and Instrumentation
Reagents and solvents for synthesis were purchased from Sigma-Aldrich, VWR Chemicals, Fisher Scientific, Panreac AppliChem, Alfa Aesar and Chemsolute and were used without further purifications (unless stated otherwise). 1 H NMR and 13 C NMR were recorded on a Bruker AMX spectrometer (Bruker, Germany) at 300 and 75 MHz respectively, where either CDCl 3 or DMSOd 6 was used as a solvent. Tetramethylsilane was used as standard and chemical shifts are reported in parts per million (ppm). Elementary analyses (C, H, N) were measured on a CHN-Rapid (Heraeus, Germany) and were within 0.4% of the theoretical values for final compounds. LC-MS analysis was performed on a Bruker Elute SP; Column: Intensity Solo C 18 RP; column dimensions: 100 x 2.1 mm; eluent: acetonitrile (1-40%) in water, 0.1% formic acid; flow: 0.3 mL/min) combined with mass spectrometric detection (Bruker amazon speed with ESI; detection: ion-trap; ion-polarity: positive; scan: 100-600 m/z). Data are given as retention time (t R ), mass number ([M  +H] + ), and normalized peak area (%) as approximated purity. Melting points (m.p., uncorrected) were determined on a M-564 Büchi melting point apparatus (Büchi, Germany). Thin-layer chromatography (TLC) was carried out using pre-coated silica gel 60 with fluorescence indicator at UV 254 nm (Macherey-Nagel, Germany). The structure and purity of each compound were confirmed 
Chemistry General Synthesis Procedures
Method A The aniline derivative (6 mmol, 1 eq) and the aromatic acid derivative (6 mmol, 1 eq) were suspended in toluene (10 mL). After heating to reflux and dissolving of the precipitate, phosphor trichloride (2.4 mmol, 0.4 eq) was added in a dropwise manner. The reaction was monitored using TLC (ethyl acetate:n-hexane 1:4). After reaction completion, the hot mixture was filtered and the organic solution was stored at 5°C. The formed precipitate was filtered off, washed with ice-cold toluene and recrystallized from toluene. 17 Method B 1,1ʹ-Carbonyldiimidazole (CDI) (9 mmol, 1.5 eq) was dissolved in THF (10 mL). To this solution the respective aromatic acid (9 mmol, 1.5 eq) was added dissolved in THF (10 mL). After 10 min stirring at room temperature, a solution of the aniline derivative (6 mmol, 1 eq) in THF (10 mL) was added. The reaction mixture was stirred for 10 min at room temperature and then refluxed overnight. After cooling to room temperature, the solvent was evaporated under reduced pressure and the residue dissolved in ethylacetate. The organic phase was then washed with saturated aqueous sodium hydrogen carbonate solution and brine. After drying over magnesium sulfate, the solvent was evaporated under reduced pressure and the residue was recrystallized from toluene.
18
Method C The respective pyridine derivative (6 mmol, 1 eq) and the benzoyl chloride derivative (6 mmol, 1 eq) were sealed in a glass vial. The reaction mixture was stirred for 4 min at 160°C under microwave irradiation. The resulting mixture was recrystallized from ethanol. 19 
Method D
The respective nitro derivative (6, 9, 26) (6 mmol, 1 eq) was dissolved in dried ethanol (20 mL). After adding Pd/C (0.6 mmol, 0.1 eq) and hydrazine monohydrate (60 mmol, 10 eq), the mixture was refluxed for 2 h and afterwards stirred for another 45 min at room temperature. Filtration via a short Celite column and evaporation of the solvent afforded the desired compounds (5, 8, 25 ).
20
Enzymology
Monoamine oxidase A/B inhibition assays were performed as described previously using the discontinuous fluorimetric method with kynuramine as MAO substrate. , 375 units mL −1 ), respectively, was added to start the reactions.
The reaction mixtures were incubated for 20 min incubation time at 37°C. All enzyme assays were conducted in pre-warmed potassium phosphate buffer (50 mM, pH = 7.4) and a final assay volume of 100 µL. Reactions were stopped by adding 35 µL sodium hydroxide solution (2 N) to the assay mixture. The enzyme activity was determined by measuring the 4-hydroxyquinoline formed during incubation time (expressed as RFU; λ Em = 405±20 nm and λ Ex = 320±20 nm). Compounds showing a MAO B inhibition >90% at 10 −6 M were evaluated for their IC 50 -values. The IC 50 curves were fitted (via nonlinear regression) either to the respective bottom plateau (graphically defined by RFUs for the at least two highest concentrations used, see Figure S12 in supplemental material) or set to zero in case when the bottom plateau was not reached with highest concentration tested (leading to "IC 50 estimates").
The highest concentrations to be tested had to be identified considering each compound's solubility and potential interfering fluorescence properties under assay conditions. Reversibility of inhibition was confirmed via preincubation of inhibitor (10 ⨰ IC 50 in preincubation setting) with MAO B (10 ng µL −1 in preincubation setting) for 0, 30, 60 and 90 min (37°C), followed by 50⨰ dilution in buffer and assayed with an excess of substrate (10 ⨰ K M final concentration) as described above. 21 Data were calculated as percentage of vehicle control (DMSO; set to 100% enzyme activity remained) for each time point. Mode of MAO B inhibition was determined by substratedependent (seven concentrations, 5 to 400 µm kynuramine) Michaelis-Menten kinetic analysis without inhibitor and in the presence of five different inhibitor concentrations (0.25⨰, 0.5⨰, 0.75⨰, 1⨰ and 2 ⨰ IC 50 ) and assayed as described above. Data were fitted using nonlinear "Competitive inhibition" fit and transformed into double reciprocal (Lineweaver-Burk) plots. The slopes of respective Lineweaver-Burk linearization were plotted against inhibitor concentration for additional K i determination. 22 All data were analyzed with GraphPad Prism 6.
Molecular Modelling
The crystal structure 2Z5X 23 was used as the representative complex structure of MAO A and the crystal structure 6FVZ 9 for MAO B. Both crystal structures were chosen due to the lipophilicity of the crystalized ligands (HRM for MAO A and E8Z for MAO B) and the presence of a peptide bond of the MAO B ligand. The enzyme structures were prepared using the Quick Prep tool in MOE 2018.0101 (Chemical Computing Group Inc., Canada) including protonation and energy minimization. Poses were generated using the Dock tool in MOE 2018.0101. A general docking was conducted. In case of MAO A, solvent was ignored. The placement method triangle matcher with the scoring function London dG was chosen. The refinement method rigid receptor with the scoring function Alpha HB was chosen.
Pharmacophore Modeling
The pharmacophore hypotheses of the MAO A and B inhibitors were constructed using the HipHop module of Discovery studio software 2.5.5. A subset of 25 representative compounds was selected and classified as active, moderately active, and inactive (Table S1 in the supplemental material). In total 16 HipHop runs were separately conducted for MAO A and MAO B ligands that ultimately generate 160 models (10 from each run) for each target by varying the types and ranges of pharmacophoric features and the number of features (Table S2 in the supplemental material). The generated models were allowed to compete in Receiver Operating Characteristic (ROC) curve analysis to assess their abilities to selectively capture diverse MAO A or MAO B inhibitors from a large list of decoys. The decoy list was prepared as described by Verdonk et al. 24 The testing sets include structurally diverse active inhibitors of 14 MAO A and 18 MAO B retrieved from literature. 14,25,26 36 decoys were selected for each active compound in the testing set retrieved from ZINC-database. The ROC testing set was screened by each pharmacophore for ROC analysis employing the "Best rigid search" option, while the conformational spaces of the compounds were generated employing the "CAESAR conformation generation option". Compounds missing one or more features were discarded from hit lists. The validity of a particular pharmacophore is assessed by the area under the curve (AUC) of the corresponding ROC curve, as well as accuracy, specificity, true positive rate, and false negative rate of the pharmacophore. Table S3 and Figure S10 in the supplemental material show the ROC performance of the best pharmacophore models generated for MAO A and MAO B. The active/ inactive classification accuracy of these models is good with ROC-AUC values of 0.779 and 0.750 for MAO A and MAO B models, respectively. Further theoretical and experimental methodology of ROC analyses are described in supplemental material.
Results and Discussion Chemistry
In 2018 the European Medicines Agency (EMA) recommended 22 biological active small molecules for market authorization. 27 All newly approved small molecules exhibit rather complex structures with the need for multistep synthesis, often including stereoselective synthesis steps. Using a one-step synthesis followed by easy purification procedures, we generated a series of promising MAO A/B inhibitors. These small entities might be of interest for the development of selective or multitargeting MAO A/B inhibitors. The substituted aromatic amides were synthesized in low to good yields via activation of the carboxylic acid using either PCl 3 or CDI. CDI was used as a coupling agent for compound 47 to prevent condensation to a substituted benzoxazole, which was the major product using PCl 3 method. For compounds 2 and 19, solvent free acylation using benzoyl chloride derivatives was performed under microwave irradiation (Figure 1 ). The aromatic amines (5, 8, 25) were obtained in excellent yields from reduction of the respective nitro derivatives (6, 9, 26) . Due to their simple structures, many of our compounds have been described previously, but to our knowledge none of them were determined as potent inhibitors for MAO A or B so far.
Biological Activity MAO A and B Inhibition
An enzyme inhibition screening at a concentration of 1 µm revealed that the synthesized anilides showed the presumed MAO inhibition potency. The majority of derivatives (32 compounds) were found to be MAO B-preferring inhibitors, while 24 compounds were not selective for either of the isoforms and only ten compounds exhibited MAO A preference (Table 1 and see Figure 2 for all compound structures). The most potent MAO inhibitors were chosen for further IC 50 evaluation. Six compounds (31, 33, 34, 39, 55, and 65) showed >90% inhibition of MAO B. The most potent MAO A-preferring inhibitor (with MAO B inhibition <50%), compound 7 was also considered for additional investigations. , and R 3 see Table 1 .
B inhibition capacity of 39, presumed depending on screening results, could not be verified in IC 50 determinations (MAO B, IC 50 >1000 nM), where assay limitations did not allow the determination of the bottom plateau due to low solubility and fluorescence crosstalk. Assuming that the real but nondetectable bottom plateau might be » 0, the previous determined percent inhibition value in one-point screening would have been overestimated (as calculated with bottom = 0). The most potent compound 55 (ST-2043) showed high inhibition of MAO B (IC 50 = 56 nM), which is in a similar range as described for the marketed drug safinamide (IC 50 = 53 nM; Table 1 According to the result of the docking experiments, surface complementarities influence the binding properties of the anilides nearly exclusively, whereas direct interactions are not involved in the binding of the presented ligands. Compounds 31, 33, and 34 showed close structural similarities and comparable inhibition properties. All of these ligands are substituted with a hydroxyl group at the 2-position of the benzylic site and a chloro substituent at the 5-position. The aniline moiety in all cases is para-substituted with a highly lipophilic residue, ie a bromo-substituent (34), a trifluoromethoxy group (33) , and a trifluoromethyl group (31) in the para-position. The interaction of these hydrophobic residues with the lipophilic cavity of the MAO B binding pocket, including the nonpolar amino acids Pro102 and Leu164, might be responsible for their potent MAO B inhibition properties. The carbonyl function of the linking amide and the hydroxyl groups in 2-position are directed towards Cys172 and interact via polar aprotic forces (see Figures S5-S7 in the supplemental material) . A similar polar system is present in pyrrolo-pyridinyl derivatives synthesized by Tzvetkov et alindicating that a central hydrogen bond donor/acceptor complex is favorable for MAO B binding. 28 The docking pose of the MAO A preferring inhibitor 7 (ST-2023) is inverted by 180°in the binding pocket of the MAO B model, where the polar nitro-group is interacted with Cys172 ( Figure 3 ). This would enlarge the distance to the FAD and could be responsible for the low MAO B activity compared with MAO A. This reversed pose was also observed in 29 The most potent inhibitor 55
(ST-2043) in this series is oriented with its piperonylic acid moiety towards the FAD (Figure 3 ). Using the same moiety, Vishnu et al designed MTLs where the piperonylic acid aligned within the hydrophobic region opposite to the FAD, and the high inhibition capacities resulted from irreversible binding via a propargyl amine residue. 30 Due to their small size and molecular weight, the presented structures are useful starting skeletons to design MTLs with MAO B activity. The docking experiments suggest using the aniline residue of 55 (ST-2043) as an attachment point to implement pharmacophores of additional targets. Zhang et al showed that larger substituents at this position are tolerated, where a bulky fluorobenzyl group is located further outside of the enzymes binding pocket than the here presented aniline groups. 31 The hypothesis that substitution at this position might be suitable for designing MTLs is coherent with the linear structures synthesized by Pisani et al that combine MAO B inhibition with nitric oxide releasing precursors and acetylcholine esterase (AChE) inhibition moieties. 32 In the MAO A binding pocket, the polar salicylic group of compounds 31, 33, 34, and 39 did not match the surrounding hydrophobic cavity, which might explain the loss of inhibition properties for MAO A (see Figures S1-S3 in the supplemental material). The three compounds, missing the salicylic moiety (7, 55, 65) , are aligned well into the MAO A active site with respect to surface complementarity, showing that small alteration in the molecular structure can have a major impact on the modulation of the MAO isoform selectivity. The modeling results are further supported by ROC-selected pharmacophore models based on inhibitors presented here (see Figure 4 and supplemental material). The essential predicted characteristics for MAO A and MAO B binding are a central hydrogen bond acceptor flanked by aromatic or hydrophobic features. This is in good accordance with the docking poses, with the limitation that the molecular docking showed no direct hydrogen bond interactions between the ligands and the amino acids of the binding pocket.
The most potent MAO B inhibitor 55 (ST-2043) was further investigated to determine mode and type of inhibition. Reversibility studies with excess of substrate verified the expected reversible mode of inhibition. Compared to the suicide inhibitor L-deprenyl, inhibition by compound 55 (ST-2043) (10-fold IC 50 concentrations) preincubated with MAO B for 30, 60 or even 90 min was completely reversed after 50-fold dilution in assays mixture ( Figure 5 ). It could be assumed, that compound 55 was readily displaced from the MAO B active side, while a more tight-binding interaction, e. g. as shown for safinamide, is considered to be more favorable in terms of pharmacological activity. 
Cholinesterase Inhibition
Cholinesterase enzymes are of potential interest in MTL drug design for the treatment of neurodegenerative diseases. 33 Therefore, compound 55 (ST-2043) was screened for inhibition of acetyl-and butyrylcholine esterases (AChE/BuChE).
At a concentration of 1 µm, 55 (ST-2043) showed only moderate inhibition capacity with 24±1.8% and 57±4.5%
for AChE and BuChE, respectively (see Table S4 and Figure S11 in supplemental material). Thus, no further characterization in this direction has been performed. 
